|drug906||Convalescent anti-SARS-CoV-2 MBT Plasma Wiki||1.00|
|drug3201||Standard Medical Treatment Wiki||0.45|
There is one clinical trial.
Aim of the study is to investigate whether the Covid-19 is found in the vaginal swab samples of female patients diagnosed with covid-19, to evaluate the presence of Covid-19 and the risk of transmission of Covid-19 by intercourse or vaginal delivery.
Description: Vaginal fluid Covid-19 test positivity rate for patients whose nasofarengeal test is positiveMeasure: Vaginal fluid Covid-19 PCR test result Time: 1 month
Description: The ratio of negative test results to previous positive results for vaginal fluid Covid-19 testMeasure: becoming negative from positive Time: 2 month
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports